Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Brad Hively will not seek Board re-election at the 2027 annual meeting.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Brad Hively will not seek Board re-election at the 2027 annual meeting
- Hively remains a director until the Annual Meeting but immediately exits Vice Chairman and all Board committees
- Company reported no disagreement with Hively regarding operations, policies, or practices
- Committee departures may affect Board oversight and governance responsibilities until succession decisions are made
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.